Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Non-Small Cell Lung Cancer (NSCLC): Update Bulletin # 2 [February 2019]

Product Code:
596201043
Publication Date:
February 2019
Format:
PDF
Price:
€1265

This edition presents the views and insights from three of the world’s foremost key opinion leaders (KOLs) from the US and EU on a variety of recent events in the non-small cell lung cancer (NSCLC) market. KOLs provide their candid insights on key events, including: the FDA approval, and the EMA’s recommendation of approval, for Tecentriq (atezolizumab; Roche), in combination with Avastin (bevacizumab; Roche), paclitaxel and carboplatin, for the first-line treatment of metastatic nonsquamous NSCLC, based on data from the IMpower150 trial; the failure of the Phase III MYSTIC trial of Imfinzi (durvalumab; AstraZeneca) as a monotherapy, or in combination with tremelimumab, to meet both its primary endpoints; the EU approval of Alunbrig (brigatinib; Takeda) as a monotherapy for the treatment of ALK-positive advanced NSCLC previously treated with crizotinib (Xalkori; Pfizer/Merck Group), based on data from the Phase II ALTA trial.

Business Questions:

• How do KOLs view the FDA approval of Tecentriq, in combination with Avastin, paclitaxel and carboplatin, for the first-line treatment of metastatic nonsquamous NSCLC?
• In which patients and to what extent will the Tecentriq quadruplet regimen be used in the treatment of NSCLC and how does it compare with Keytruda?
• How do KOLs react to the failure of the MYSTIC trial of Imfinzi as a monotherapy, or in combination with tremelimumab, to meet its OS and PFS in patients with metastatic NSCLC, compared with platinum-based chemotherapy?
• Subset analysis of the MYSTIC data revealed a potential benefit for Imfinzi in the first-line treatment of patients with high PD-L1 expression or high tumour mutation burden. Could Imfinzi find a role in the treatment of these patient subsets?
• Despite the failure of the MYSTIC trial, the Phase III NEPTUNE and POSEIDON studies continue to evaluate Imfinzi as a first-line therapy for advanced or metastatic NSCLC. Could there be a potential role for Imfinzi as a frontline therapy, and what could help it compete?
• How do KOLs view the ALTA data and the EU approval of Alunbrig as a monotherapy for the treatment of patients with ALK-positive advanced NSCLC previously treated with Xalkori?
• In which patients and to what extent will Alunbrig be used in the treatment of ALK-positive advanced NSCLC?

 




customer.service@firstwordpharma.com

All Contents Copyright © 2019 Doctor's Guide Publishing Limited All Rights Reserved